AUCTORES
Globalize your Research

Journal of Brain and Neurological Disorders
Mahdi Naeim *

Open Access

Short communication

Emerging Therapeutic Approaches for Parkinson's Disease and Movement Disorders

Mahdi Naeim

Research Department, Psychology and Counselling Organization, Tehran, Iran.

***Corresponding Author:** Mahdi Naeim, Research Department, Psychology and Counselling Organization, Tehran, Iran.

Received Date: 05 February 2024 | **Accepted Date:** 15 February 2024 | **Published Date:** 27 February 2024

Citation: Mahdi Naeim, (2024), Emerging Therapeutic Approaches for Parkinson's Disease and Movement Disorders, *J. Brain and Neurological Disorders*. 7(2): **DOI: 10.31579/2642-973X/098**

Abstract

An overview of the newest treatment modalities for Parkinson's disease and movement disorders is given in this paper. Motor deficits are a defining feature of neurological illnesses such as Parkinson's disease and movement disorders. The article focuses on the most recent developments in therapeutic approaches, such as targeted pharmaceutical medicines, deep brain stimulation (DBS), gene therapy, cell replacement therapy, and newly developed non-invasive procedures. These strategies seek to improve dopamine function, address underlying causes, improve symptom control, and offer possibilities for precision therapy. The study highlights how these new treatments have the potential to completely change the treatment and outlook for people with Parkinson's disease and other movement disorders.

Key Words: parkinson's disease; movement disorders; emerging therapeutic approaches; deep brain stimulation; gene therapy

Introduction

Movement disorders, including Parkinson's disease (PD), are a spectrum of neurodegenerative illnesses marked by motor function abnormalities. These illnesses provide major difficulties for patients as well as medical professionals around the globe [1]. This study examines the most recent developments in treatment modalities for movement disorders and Parkinson's disease, emphasizing novel tactics that could enhance patient outcomes.

Deep Brain Stimulation (DBS): Enhancing Symptom Control

One well-known neurosurgical treatment for Parkinson's disease and other movement disorders is deep brain stimulation (DBS). Electrodes are inserted into predetermined brain areas, and then electrical impulses are delivered to adjust neural activity. It has been demonstrated that DBS is remarkably effective in reducing motor symptoms such as bradykinesia, stiffness, and tremors. To maximize symptom control and reduce side effects, ongoing research aims to improve programming algorithms, pinpoint the best stimulation targets, and hone DBS procedures [2].

Gene Therapy: Targeting Underlying Causes

Targeting the underlying genetic or molecular defects, gene therapy holds great promise for treating Parkinson's disease and other movement disorders. The goal of experimental gene therapies is to return normal function to damaged cells by introducing therapeutic genes. To restore dopamine levels in the brain, for instance, ongoing clinical trials are looking into the use of viral vectors to transfer genes encoding enzymes involved in dopamine production. Although gene therapies are still in their infancy, they present encouraging paths toward long-term disease modification and possible treatments [3].

Cell Replacement Therapy: Restoring Dopaminergic Function

To replace the missing or damaged neurons in Parkinson's disease, dopaminergic cells are transplanted into the brain as part of cell replacement treatment. Therapeutics based on stem cells, such as induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs), can produce dopaminergic cells that are unique to each patient. New understandings of the growth and transplantation of these cells have been made possible by recent developments in stem cell research and regenerative medicine. There are still issues to be resolved, such as maximizing cell survival, integration, and functional development; also, possible immunological reactions and moral dilemmas must be taken into account [4].

Targeted Pharmacological Therapies: Precision Medicine Approaches

The development of targeted pharmaceutical therapy for Parkinson's disease and other movement disorders has been made possible by advances in molecular biology and our comprehension of disease mechanisms. These strategies entail the creation of medications that precisely alter molecular targets or disease-related pathways. For example, preclinical and clinical trials are being conducted to examine potential medications that target inflammation, mitochondrial failure, or alpha-synuclein aggregation. The selection of the best course of treatment for better therapeutic outcomes may be made possible by precision

medicine techniques that take into account unique patient characteristics, such as genetic profiles or biomarkers [5].

Emerging Non-Invasive Therapies: Expanding Treatment Options

The use of non-invasive therapies as possible supplements or substitutes for conventional treatment methods for Parkinson's disease and movement disorders is growing. Transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) are examples of non-invasive brain stimulation treatments that affect neuronal activity without requiring invasive procedures. These methods appear to be promising in improving cortical plasticity and mitigating motor symptoms. Furthermore, novel technologies that can non-invasively target particular brain regions and modify neuronal activity—like focused ultrasound—are being investigated [6].

Conclusion

Treatments for Parkinson's disease and movement disorders are developing at a rapid pace. Innovative non-invasive methods, focused pharmaceutical therapies, deep brain stimulation, gene therapy, cell replacement therapy, and tailored pharmaceutical therapies provide novel ways to improve patient outcomes and reduce symptoms. To turn these promising methods into practical and affordable medicines, academics, doctors, and industry partners must continue their cooperation as research advances. Ultimately, the treatment and prognosis of people with Parkinson's disease and movement disorders could be completely transformed by incorporating these cutting-edge treatments into all-encompassing management plans.

References

1. Troncoso-Escudero P, Sepulveda D, Pérez-Arancibia R, Parra AV, Arcos J, Grunenwald F, Vidal RL. (2020). On the right track to treat movement disorders: promising therapeutic approaches for Parkinson's and Huntington's disease. Frontiers in Aging Neuroscience. Sep 3;12:571185.
2. Guzick A, Hunt PJ, Bijanki KR, Schneider SC, Sheth SA, Goodman WK, Storch EA. (2020).Improving long term patient outcomes from deep brain stimulation for treatment-refractory obsessive-compulsive disorder. Expert review of neurotherapeutics. Jan 2;20(1):95-107.
3. Pena SA, Iyengar R, Eshraghi RS, Bencie N, Mittal J, Aljohani A, Mittal R, Eshraghi AA. (2020).Gene therapy for neurological disorders: challenges and recent advancements. Journal of drug targeting. Feb 7;28(2):111-128.
4. Fan Y, Winanto, Ng SY. (2020).Replacing what's lost: a new era of stem cell therapy for Parkinson's disease. Translational Neurodegeneration. Dec;9:1-10.
5. Li D, Mastaglia FL, Fletcher S, Wilton SD. (2020).Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era. Medicinal Research Reviews. Nov;40(6):2650-2681.
6. Madrid J, Benninger DH. (2021).Non-invasive brain stimulation for Parkinson's disease: Clinical evidence, latest concepts and future goals: A systematic review. Journal of Neuroscience Methods. 2021 Jan 1;347:108957.

DOI:10.31579/2642-973X/098